Curcumin ameliorates autoimmune diabetes. Evidence in accelerated murine models of type 1 diabetes

C N Castro1, A E Barcala Tabarrozzi, J Winnewisser

  • 1Instituto de Investigación en Biomedicina de Buenos Aires (IBioBA), CONICET - Partner Institute of the Max Planck Society, Buenos Aires, Argentina.

Insights

Curcumin, a natural compound, may treat type 1 diabetes by reducing harmful T cell responses and inflammation, protecting insulin-producing cells. This research explores curcumin

Area of Science:

  • Immunology
  • Endocrinology
  • Pharmacology

Background:

  • Type 1 diabetes (T1DM) is an autoimmune disease targeting pancreatic beta cells.
  • Current treatments focus on managing hyperglycemia, not curing the underlying autoimmunity.

Purpose of the Study:

  • To investigate curcumin's potential to modulate T cell responses and prevent autoimmune diabetes.
  • To elucidate the mechanisms by which curcumin exerts its protective effects.

Main Methods:

  • Utilized two accelerated autoimmune diabetes models in non-obese diabetic (NOD) mice.
  • Administered cyclophosphamide (CYP) and performed adoptive transfer of diabetogenic splenocytes.
  • Assessed the impact of curcumin on T cell proliferation, cytokine production (IFN-γ), transcription factors (T-bet), signaling pathways (NF-κB), and dendritic cell function.

Main Results:

  • Curcumin significantly delayed or prevented autoimmune diabetes onset.
  • Curcumin inhibited pancreatic leukocyte infiltration and preserved insulin-expressing cells.
  • Curcumin modulated T lymphocyte responses, reducing proliferation and IFN-γ production via T-bet regulation.
  • Curcumin decreased NF-κB activation and impaired dendritic cell stimulatory function.

Conclusions:

  • Curcumin demonstrates therapeutic potential for autoimmune diabetes.
  • Curcumin acts on key immune cells, including T lymphocytes and dendritic cells, to reduce autoimmune attack on beta cells.
  • These findings support curcumin as a potential agent for managing T1DM by targeting its autoimmune basis.

Related Concept Videos

Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular...
75
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1...
45
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.5K